다발성 경화증 치료제 파이프라인 분석 - 2026년(Q2 인사이트 및 임상시험)

The Multiple Sclerosis drug pipeline is rapidly evolving as pharmaceutical and biotechnology companies develop next-generation therapies designed to reduce disability progression, preserve neuronal function, promote remyelination, and improve long-term neurological outcomes across both relapsing and progressive forms of multiple sclerosis.

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by inflammatory demyelination, axonal degeneration, and progressive neurological disability. Although currently approved disease-modifying therapies effectively reduce inflammatory disease activity and relapse rates, significant unmet needs remain in treating progressive disease, promoting myelin repair, and preventing long-term disability. Drug pipeline analysis provides comprehensive insights into investigational therapies, clinical development phases, mechanisms of action, drug modalities, sponsor activities, regulatory developments, and future commercialization opportunities.

Market Drivers

Expanding Development of Next-Generation Disease-Modifying Therapies

• The increasing demand for therapies capable of slowing disability progression beyond relapse control continues to drive pipeline expansion. Pharmaceutical companies are investing heavily in innovative treatments targeting immune modulation, remyelination, neuroprotection, and regenerative medicine.

Growing Investment in Precision Immunology

• Advances in immunology and molecular neuroscience have accelerated the development of therapies that selectively regulate immune responses while minimizing systemic immunosuppression. Bruton tyrosine kinase (BTK) inhibitors, antigen-specific immune tolerance therapies, and biomarker-guided treatment strategies are becoming major areas of pipeline investment.

Increasing Focus on Progressive Multiple Sclerosis

• Growing recognition of the limited treatment options available for secondary progressive and primary progressive multiple sclerosis has encouraged developers to prioritize therapies capable of reducing disability progression and preserving neurological function.

Advances in Drug Discovery Technologies

• Artificial intelligence, computational drug discovery, genomic medicine, advanced imaging biomarkers, and digital clinical trial technologies are improving target identification, patient selection, and clinical development efficiency, accelerating pipeline advancement.

Market Restraints

Complex Disease Biology

• The heterogeneous nature of multiple sclerosis, including relapsing-remitting, secondary progressive, and primary progressive disease forms, creates significant challenges in identifying broadly effective therapies and designing successful clinical trials.

Lengthy Clinical Development

• Drug development for multiple sclerosis requires extensive long-term evaluation of relapse reduction, disability progression, MRI outcomes, and safety, resulting in prolonged development timelines and substantial research investment.

Stringent Regulatory Requirements

• Regulatory agencies require comprehensive evidence demonstrating durable efficacy, long-term safety, patient-reported outcomes, and meaningful reductions in disability progression, increasing development complexity.

Pipeline and Technology Insights

• The global multiple sclerosis drug pipeline can be segmented by clinical development phase, mechanism of action, drug modality, target patient population, and geography.
• By clinical development phase, the pipeline includes preclinical, Phase I, Phase II, Phase III, and filed or under regulatory review assets. Mid-stage development remains highly active, while late-stage programs increasingly focus on therapies addressing progressive disease and long-term disability.
• By mechanism of action, the pipeline includes immunomodulators, B-cell targeted therapies, T-cell modulators, BTK inhibitors, remyelination therapies, neuroprotective therapies, antigen-specific immune tolerance therapies, stem cell-based therapies, and other emerging mechanisms. BTK inhibitors and remyelination therapies currently represent two of the most competitive and rapidly expanding areas of development.
• By drug modality, investigational products include small molecules, biologics, cell therapies, gene therapies, RNA therapeutics, and combination therapies. Small molecules continue to dominate pipeline activity, while regenerative medicine and gene-based approaches are expanding rapidly as scientific understanding improves.
• By target patient population, therapies are being developed for relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS), clinically isolated syndrome (CIS), and broader multiple sclerosis populations. Increasing emphasis is being placed on therapies capable of addressing progressive disease, where significant unmet clinical needs remain.
• Technological advances including artificial intelligence, digital biomarkers, advanced MRI imaging, neurofilament light chain biomarkers, decentralized clinical trials, wearable monitoring devices, and real-world evidence platforms continue to improve drug development efficiency and clinical decision-making.

Pipeline Development Trends

• The multiple sclerosis pipeline continues to diversify beyond conventional anti-inflammatory approaches toward therapies capable of modifying disease progression.

Major pipeline trends include:

• Rapid expansion of BTK inhibitor development programs.
• Increasing investment in remyelination and regenerative therapies.
• Growing focus on neuroprotective treatment strategies.
• Expansion of biomarker-guided precision medicine.
• Increased adoption of artificial intelligence in drug discovery.
• Strategic collaborations between biotechnology companies and multinational pharmaceutical organizations.
• Greater emphasis on therapies targeting progressive multiple sclerosis rather than relapse control alone.

Regional Insights

• North America remains the leading region for multiple sclerosis drug development due to advanced neuroscience research infrastructure, strong pharmaceutical investment, extensive clinical trial activity, and a large diagnosed patient population.
• Europe continues to play a major role through collaborative academic research, established neurological treatment centers, and harmonized regulatory guidance supporting multinational clinical development.
• Asia-Pacific is expected to experience the fastest growth during the forecast period owing to expanding biotechnology capabilities, improving neurological care infrastructure, increasing investment in research, and growing participation in multinational clinical trials across China, Japan, South Korea, India, and Australia.
• Latin America and the Middle East & Africa are gradually strengthening clinical research capabilities through healthcare modernization, improved diagnostic services, and increased participation in international development programs.

Competitive Landscape

• The multiple sclerosis drug pipeline includes multinational pharmaceutical companies, biotechnology firms, academic research institutions, contract research organizations, and neuroscience-focused innovators.
• Companies continue to invest in differentiated immunotherapies, regenerative medicine, biomarker-guided development, artificial intelligence-assisted drug discovery, and precision medicine technologies. Strategic licensing agreements, mergers and acquisitions, co-development partnerships, and research collaborations remain essential for strengthening development pipelines and accelerating commercialization.
• Competition increasingly focuses on therapies capable of slowing disability progression, promoting remyelination, preserving neuronal integrity, and improving long-term functional outcomes.

Future Outlook

• The future of the multiple sclerosis drug pipeline is expected to be shaped by advances in neuroimmunology, regenerative medicine, precision immunology, biomarker science, artificial intelligence, and personalized neurology. Future innovation will increasingly emphasize therapies capable of modifying disease progression, repairing myelin damage, and preventing irreversible neurological disability rather than controlling inflammation alone.
• Growing integration of digital biomarkers, adaptive clinical trial designs, real-world evidence, and precision medicine technologies is expected to improve development success rates while accelerating regulatory approvals and commercialization.

Conclusion

The global Multiple Sclerosis Drug Pipeline Analysis market is expected to experience sustained growth through 2035, supported by expanding investment in neuroscience research, increasing development of next-generation disease-modifying therapies, advances in regenerative medicine, and growing adoption of precision immunology. Although challenges including disease heterogeneity, lengthy clinical development, and regulatory complexity remain, ongoing innovation in BTK inhibitors, remyelination therapies, neuroprotective agents, biomarker-guided treatment, and artificial intelligence is expected to transform the future therapeutic landscape and create significant opportunities for pharmaceutical companies, biotechnology firms, investors, and healthcare providers.

Key Benefits of this Report

• Comprehensive analysis of the global multiple sclerosis drug pipeline and future development trends.
• Detailed evaluation of investigational therapies, mechanisms of action, and clinical development phases.
• Competitive assessment of leading developers, pipeline assets, and strategic collaborations.
• Insights into regulatory developments, commercialization opportunities, and innovation strategies.
• Valuable resource for pharmaceutical companies, biotechnology firms, researchers, investors, healthcare providers, consultants, and policymakers.

What Businesses Use Our Reports For

• Pipeline benchmarking, competitive intelligence, portfolio optimization, licensing and partnership evaluation, investment analysis, clinical development planning, commercialization strategy, regulatory planning, and identification of emerging therapeutic opportunities.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the multiple sclerosis drug pipeline by clinical development phase, mechanism of action, drug modality, target patient population, and geography
• Evaluation of investigational therapies, pipeline maturity, sponsor activities, regulatory developments, and innovation trends
• Assessment of licensing agreements, strategic collaborations, mergers and acquisitions, and competitive positioning
• Analysis of emerging technologies, precision immunology, regenerative medicine, biomarker integration, and future commercialization opportunities through 2035.

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Research Methodology
• 1.2. Research Scope
  • 1.2.1. Analysis by Company
  • 1.2.2. Analysis by Development Phase
  • 1.2.3. Analysis by Intervention Type
  • 1.2.4. Analysis by Clinical Trial Status
  • 1.2.5. Analysis by Geography
• 1.3. Data Sources and Validation
• 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

• 2.1. Introduction
• 2.2. Disease Classification
• 2.3. Causes and Risk Factors
• 2.4. Symptoms and Clinical Manifestations
• 2.5. Diagnosis
• 2.6. Current Treatment Landscape
• 2.7. Epidemiology and Disease Burden
• 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

• 3.1. Clinical-Stage Pipeline Overview
• 3.2. Pipeline Distribution by Development Phase
• 3.3. Leading Companies by Clinical Trial Activity
• 3.4. Leading Investigational Drugs and Interventions
• 3.5. Geographic Clinical Trial Landscape
• 3.6. Key Pipeline Trends and Findings

4. MULTIPLE SCLEROSIS PIPELINE DYNAMICS

• 4.1. Drivers
• 4.2. Restraints
• 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

• 5.1. PIPELINE ANALYSIS BY COMPANY
  • 5.1.1. Novartis
  • 5.1.2. Sanofi
  • 5.1.3. F. Hoffmann-La Roche
  • 5.1.4. Merck KGaA
  • 5.1.5. Biogen
• 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
  • 5.2.1. Early Phase I
  • 5.2.2. Phase I
  • 5.2.3. Phase I/II
  • 5.2.4. Phase II
  • 5.2.5. Phase II/III
  • 5.2.6. Phase III
• 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
  • 5.3.1. Drug
  • 5.3.2. Biological
  • 5.3.3. Genetic
• 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
  • 5.4.1. Relapsing-Remitting MS
  • 5.4.2. Secondary Progressive MS
  • 5.4.3. Primary Progressive MS
  • 5.4.4. Clinically Isolated Syndrome
• 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
  • 5.5.1. Not Yet Recruiting
  • 5.5.2. Recruiting
  • 5.5.3. Active, Not Recruiting
  • 5.5.4. Completed
  • 5.5.5. Terminated / Withdrawn / Suspended
• 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia-Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa
• 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
  • 5.7.1. Clinical Trials by Patient Enrollment
  • 5.7.2. Clinical Trials by Study Design
  • 5.7.3. Patient Age Eligibility
  • 5.7.4. Patient Sex Eligibility
• 5.8. SPONSOR AND COLLABORATION ANALYSIS
  • 5.8.1. Leading Commercial Sponsors
  • 5.8.2. Leading Academic and Research Sponsors
  • 5.8.3. Leading Collaborating Organizations
  • 5.8.4. Sponsor-Collaborator Analysis
• 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
  • 5.9.1. Recently Initiated Clinical Trials
  • 5.9.2. Newly Recruiting Clinical Trials
  • 5.9.3. Recently Completed Clinical Trials
  • 5.9.4. Late-Stage Trials Approaching Primary Completion
  • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

• 6.1. Novartis
• 6.2. Sanofi
• 6.3. F. Hoffmann-La Roche
• 6.4. Merck KGaA
• 6.5. Biogen

7. LIST OF TABLES

8. LIST OF FIGURES